299. 嚢胞性線維症 Cystic fibrosis Clinical trials / Disease details


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

  
23 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04731272
(ClinicalTrials.gov)
April 20, 202126/1/2021GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose IntoleranceEffect of GLP-1 Agonist Therapy on Insulin Secretion in Adults With Pancreatic Insufficient Cystic Fibrosis and Abnormal Glucose Tolerance: a Randomized, Open-label, Cross-over TrialCystic Fibrosis;Pancreatic Insufficiency;Abnormal Glucose Tolerance;DiabetesDrug: Dulaglutide 0.75Mg/0.5Ml Inj PenUniversity of PennsylvaniaChildren's Hospital of PhiladelphiaRecruiting18 YearsN/AAll30Phase 2United States
2NCT04533646
(ClinicalTrials.gov)
March 17, 202123/8/2020Comparison of Meal-Time Dosing of Insulin in Cystic Fibrosis Related DiabetesComparison of Meal-Time Dosing of Rapid Acting Insulin Using Carbohydrate Counting vs. Fixed Doses Utilizing Continuous Glucose Monitoring In Patients With Cystic Fibrosis Related DiabetesCystic Fibrosis-related DiabetesDrug: Insulin;Device: Continuous glucose monitor (CGM)Jagdeesh UllalWake Forest University Health SciencesRecruiting18 Years80 YearsAll20Phase 4United States
3NCT04381429
(ClinicalTrials.gov)
August 17, 202030/4/2020Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related DiabetesEffect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes : MIRE TrialCystic Fibrosis-related DiabetesDrug: A-F-A-F (NovoRapid-FIASP-NovoRapid-FIASP);Drug: F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid)University Hospital, Strasbourg, FranceNULLRecruiting10 YearsN/AAll40Phase 4France
4NCT01879228
(ClinicalTrials.gov)
June 201312/6/2013Effect of Chronic Incretin-based Therapy in Cystic FibrosisA Randomized, Double-blind, Placebo Controlled Study of the Effectiveness of Chronic Incretin-based Therapy on Insulin Secretion in Cystic FibrosisCystic Fibrosis;Pancreatic InsufficiencyDrug: SitagliptinUniversity of PennsylvaniaChildren's Hospital of PhiladelphiaCompleted18 YearsN/AAll26N/AUnited States
5NCT01852448
(ClinicalTrials.gov)
May 20139/5/2013Genetics of Insulin and Incretins in Cystic FibrosisEvaluation of the Enteroinsular Axis in Cystic FibrosisCystic FibrosisGenetic: Blood or Saliva Sample CollectionChildren's Hospital of PhiladelphiaUniversity of PennsylvaniaRecruiting2 YearsN/AAll550United States
6EUCTR2012-002880-86-GB
(EUCTR)
25/01/201309/11/2012Resting the pancreas in Cystic FibrosisPRESERVING ?ETA-CELLS: ‘RESTING THE PANCREAS’ IN CYSTIC FIBROSIS Cystic Fibrosis Related Diabetes (CFRD)
MedDRA version: 14.1;Level: LLT;Classification code 10022468;Term: Insulin;System Organ Class: 100000004848;Therapeutic area: Body processes [G] - Physiological processes [G07]
Trade Name: Levemir FlexPen
Product Name: Levemir FlexPen
Liverpool Heart and Chest Hospital NHS TrustNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
United Kingdom
7EUCTR2011-001916-69-NL
(EUCTR)
22/05/201207/02/2012treatment with insulin in patients with cystic fibrosis without diabetesinsulin therapy in non-diabetic adults with cystic fibrosis - insulin in CF without CFRD cystic fibrosis patients without cystic fibrosis related diabetes;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]Trade Name: Lantus 100 units/ml solution for injection in a cartridgeHagaZiekenhuis, pulmonary departmentNULLNot RecruitingFemale: yes
Male: yes
40Netherlands
8EUCTR2011-002719-27-IT
(EUCTR)
30/12/201113/03/2012EFFECT OF RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-I ON GLUCOSE TOLERANCE AND AS PREVENTION TOWARDS THE DEVELOPMENT OF CYSTIC FIBROSIS RELATED DIABETES MELLITUSGLUCOSE METABOLISM AND INFLAMMATORY PARAMETERS UNDER IGF-I TREATMENT IN CYSTIC FIBROSIS - RH-IGF-I IN CYSTIC FIBROSIS PATIENTS WITH CYSTIC FIBROSIS
MedDRA version: 14.1;Level: PT;Classification code 10011766;Term: Cystic fibrosis pancreatic;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: INCRELEX*SC 1FL 4ML 10MG/ML
INN or Proposed INN: MECASERMIN
AZIENDA OSPEDALIERA DI PARMANULLNot RecruitingFemale: yes
Male: yes
20Italy
9NCT01100892
(ClinicalTrials.gov)
December 201031/3/2010Cystic Fibrosis - Insulin Deficiency, Early ActionCystic Fibrosis - Insulin Deficiency, Early ActionCystic Fibrosis;DiabetesDrug: Once-daily insulin detemirSydney Children's Hospitals NetworkJohn Hunter Children's Hospital;Lady Cilento Children's Hospital, Brisbane;Women's and Children's Hospital, Adelaide;Children's Hospital ColoradoActive, not recruiting5 Years19 YearsAll100Phase 3United States;Australia
10NCT01149005
(ClinicalTrials.gov)
June 20109/6/2010Cystic Fibrosis (CF) Exacerbation and Insulin TreatmentEvaluation of Glucose Tolerance and Insulin Treatment in Non Diabetic Patients With Cystic Fibrosis During Acute Pulmonary ExacerbationCystic Fibrosis;Impaired Glucose Tolerance;Pulmonary ExacerbationDrug: novorapid / humalog short acting insulin;Drug: Novo Rapid Insulin (Novonordisk)Hadassah Medical OrganizationNULLNot yet recruiting10 YearsN/ABoth30N/AIsrael
11EUCTR2009-009875-37-NL
(EUCTR)
11/03/200921/01/2009A placebo-controlled trial of insulin therapy with or without adjuvant metformin in patients with cystic fibrosis-related diabetes - Insulin therapy and adjuvant metformin in CFRDA placebo-controlled trial of insulin therapy with or without adjuvant metformin in patients with cystic fibrosis-related diabetes - Insulin therapy and adjuvant metformin in CFRD Cystic fibrosis-related diabetes
MedDRA version: 9.1;Level: HLT;Classification code 10012602;Term: Diabetes mellitus (incl subtypes)
MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis
Trade Name: Metformine HCL 500 PCHStaf LongziektenNULLNot RecruitingFemale: yes
Male: yes
25Netherlands
12EUCTR2007-004956-35-GB
(EUCTR)
27/08/200826/11/2007The effect of intensive blood glucose control with insulin on markers of short and medium term outcomes in patients hospitalised with acute exacerbations of chronic lung disease. Pilot Study to test feasibility and safety of a clinical protocol for intensive blood glucose control with insulin on medical wards - Pilot of Intensive Blood Glucose Control with Insulin on Medical WardsThe effect of intensive blood glucose control with insulin on markers of short and medium term outcomes in patients hospitalised with acute exacerbations of chronic lung disease. Pilot Study to test feasibility and safety of a clinical protocol for intensive blood glucose control with insulin on medical wards - Pilot of Intensive Blood Glucose Control with Insulin on Medical Wards Acute exacerbations of chronic obstructive pulmonary disease. Stress hyperglycaemia. Insulin-induced hypoglycaemia. Cystic fibrosis
MedDRA version: 9.1;Level: LLT;Classification code 10010953;Term: COPD exacerbation
MedDRA version: 9.1;Classification code 10060439;Term: Stress induced hyperglycaemia
MedDRA version: 9.1;Classification code 10022484;Term: Insulin hypoglycaemia
MedDRA version: 9.1;Classification code 10011762;Term: Cystic fibrosis
Trade Name: Actrapid 100 IU/ml, Solution for injection in a vial
Trade Name: Levemir 100 U/ml solution for injection in a cartridge, Levemir 100 U/ml solution for injection in a pre-filled pen
Trade Name: NovoRapid 100 U/ml, solution for injection in a vial. NovoRapid Penfill 100 U/ml, solution for injection in a cartridge. NovoRapid FlexPen 100 U/ml, solution for injection in a pre-filled pen.
Trade Name: Lantus® 100 Units/ml solution for injection in a vial. Lantus® 100 Units/ml solution for injection in a cartridge. Lantus® 100 Units/ml solution for injection in a pre-filled pen
St George's, University of LondonNULLNot RecruitingFemale: yes
Male: yes
United Kingdom
13NCT00639626
(ClinicalTrials.gov)
August 200814/3/2008Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)Use of Levemir® Improves Metabolic and Clinical Status in CFRDCystic Fibrosis Related DiabetesDrug: insulin detemir [rDNA origin] injectionNationwide Children's HospitalNovo Nordisk A/STerminated16 Years45 YearsAll6Phase 2/Phase 3United States
14EUCTR2006-001254-27-FR
(EUCTR)
30/11/200625/08/2006Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitusOpen randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus Patients atteints de mucoviscidose, chez lesquels un diagnostic de diabète a été fait par hyperglycémie provoquée orale (HGPO)
MedDRA version: 8.1;Level: PT;Classification code 10012594;Term: DIABETES
Trade Name: NovoNorm 0.5 mg
Product Name: NovoNorm 0.5 mg
INN or Proposed INN: Répaglinide
Trade Name: Actrapid Penfill 100UI/ml
Product Name: Actrapid Penfill 100UI/ml
INN or Proposed INN: Insuline humaine recombinante
Trade Name: NovoNorm 1 mg
Product Name: NovoNorm 1 mg
INN or Proposed INN: Répaglinide
Trade Name: NovoNorm 2 mg
Product Name: NovoNorm 2 mg
INN or Proposed INN: Répaglinide
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
France
15EUCTR2005-002997-31-GB
(EUCTR)
10/08/200609/11/2005A multi-centre randomised trial of insulin detemir in pre-diabetes associated with cystic fibrosis. - Randomized trial of insulin detemir in CF associated pre-diabetesA multi-centre randomised trial of insulin detemir in pre-diabetes associated with cystic fibrosis. - Randomized trial of insulin detemir in CF associated pre-diabetes Individuals with cystic fibrosis develop diabetes. They exhibit abnormal glucose handling (impaired glucose tolerance), poor growth and a decline in lung function before overt diabetes develops. Early treatment with insulin before diabetes develops may improve weight gain and lung function and delay progression to overt diabetes.Product Name: Levemir PenfillSheffield Children's NHS TrustNULLNot Recruiting Female: yes
Male: yes
40 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesUnited Kingdom
16NCT00287456
(ClinicalTrials.gov)
February 2, 20062/2/2006Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients.Cystic Fibrosis Related DiabetesDevice: Insulin Pump;Drug: Insulin;Procedure: Oral Glucose Tolerance Test;Procedure: Whole body Protein TurnoverUniversity of Texas Southwestern Medical CenterNULLWithdrawn12 Years32 YearsAll0N/AUnited States
17NCT00231192
(ClinicalTrials.gov)
October 20053/10/2005Repaglinide for Adolescents With Cystic Fibrosis-Related DiabetesRepaglinide for Adolescents With Cystic Fibrosis-Related DiabetesDiabetesDrug: Repaglinide and InsulinChildren's Hospital of PhiladelphiaNULLWithdrawn12 Years20 YearsBoth0N/AUnited States
18NCT00687466
(ClinicalTrials.gov)
August 200527/5/2008Study on the Efficacy of Slow Release Insulin in Cystic Fibrosis Patients With Glucide Intolerance and Clinical DecayPhase 3 Study on the Efficacy of Slow Release Insulin in Cystic Fibrosis Patients With Glucide Intolerance and Clinical DecayCystic Fibrosis;Glucose IntoleranceDrug: InsulinFondazione per la ricerca sulla Fibrosi CisticaNULLActive, not recruiting10 Years70 YearsBoth70Phase 3Italy
19EUCTR2005-002135-27-IT
(EUCTR)
06/07/200528/06/2005Glargine insulin efficacy in Cystic Fibrosis patients with glucose intolerance and clinical deteriorationGlargine insulin efficacy in Cystic Fibrosis patients with glucose intolerance and clinical deterioration Cystic Fibrosis patients with glucose intolerance
MedDRA version: 6.1;Level: PT;Classification code 10011762
Trade Name: LANTUS*SC 5CAR3ML100UI/ML
Product Name: NA
Product Code: NA
INN or Proposed INN: Insulin glargine
ISTITUTO GIANNINA GASLININULLNot RecruitingFemale: yes
Male: yes
Italy
20NCT00222521
(ClinicalTrials.gov)
April 200314/9/2005Insulin Glargine Vs Standard Insulin TherapyComparison of Insulin Glargine Vs Standard Insulin Therapy in CFRD Without Fasting HyperglycemiaCystic Fibrosis Related DiabetesDrug: Glargine insulinUniversity of Minnesota - Clinical and Translational Science InstituteSanofi;Moran, Antoinette, M.D.Completed12 YearsN/ABoth20Phase 3United States
21NCT00662714
(ClinicalTrials.gov)
September 200117/4/2008Early Diagnosis of Diabetes Mellitus in Patients With Cystic FibrosisOpen Randomised Prospective Comparative Multi-centre Intervention Study of Patients With Cystic Fibrosis and Early Diagnosed Diabetes MellitusCystic Fibrosis;Diabetes MellitusDrug: Repaglinide;Drug: short-acting Insulin (Actrapid)Mukoviszidose Institut gGmbHNovo Nordisk A/S;Mucoviscidose-ABCF2;Assistance Publique - Hôpitaux de ParisCompleted10 YearsN/ABoth73Phase 3Austria;France;Germany;Italy
22NCT00072904
(ClinicalTrials.gov)
June 200112/11/2003Diabetes Therapy to Improve BMI and Lung Function in CFDiabetes Therapy to Improve BMI and Lung Function in CFCystic Fibrosis;Diabetes MellitusDrug: Insulin Asparte;Drug: RepaglinideNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Cystic Fibrosis Foundation Therapeutics;Novo Nordisk A/SCompleted16 YearsN/ABoth108Phase 3United States;Canada
23NCT00014768
(ClinicalTrials.gov)
February 200110/4/2001Study of Metabolic Effects of Pregnancy in Women With Cystic FibrosisCystic FibrosisDrug: glucose;Drug: insulin;Drug: leucineNational Center for Research Resources (NCRR)University of UtahTerminatedN/AN/AFemale36N/AUnited States